Lexicon Pharma rallies on Fast Track tag for LX9211 in diabetic neuropathic pain

 

• Lexicon Pharmaceuticals (NASDAQ:LXRX) soars 44% premarket after receiving Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.
• Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
• Lexicon is currently enrolling patients with diabetic neuropathic pain in a Phase 2 study of LX9211 and is preparing to initiate a second Phase 2 trial of LX9211 in post-herpetic neuralgia.
• Peripheral neuropathy is nerve damage caused by chronically high blood sugar and diabetes. It leads to numbness, loss of sensation, and sometimes pain in feet, legs, or hands.
• https://seekingalpha.com/news/3643656-lexicon-pharma-rallies-44-on-fast-track-tag-for-lx9211-in-diabetic-neuropathic-pain